🧠 Neuroregression & SSPE - Viva Questions & Examiner Answers

1. Clinical Approach & Algorithmic Localization of Neuroregression

Viva Question / Counter-QuestionModel Examiner-Grade Answer
Define Neuroregression and explain how you distinguish it from Developmental Delay and Developmental Arrest at the bedside.• Neuroregression (Neurodegeneration): The unambiguous, progressive loss of previously attained and mastered developmental milestones in one or more functional domains.
• Developmental Delay: A slower-than-normal rate of developmental milestone acquisition, but the child continues to make forward progress without losing skills.
• Developmental Arrest / Plateau: A cessation of new milestone acquisition where the child neither gains new milestones nor loses previously acquired skills.

VIVA TRAP: Beware of "apparent regression" in cerebral palsy where growing contractures and increasing body weight make walking difficult (growing into a deficit); this is not true neuroregression because cognitive, language, and cortical neural networks are preserved without progressive biological loss.
Counter-Question: How do you clinically compartmentalize neuroregression into Grey Matter vs. White Matter vs. Basal Ganglia disease?1. Grey Matter (Poliodystrophy): Early intractable seizures / myoclonus, early dementia, intellectual and personality decay, macular cherry-red spot or retinal degeneration, with motor function preserved until late (e.g., SSPE, Batten disease, Tay-Sachs).
2. White Matter (Leukodystrophy): Early motor loss, progressive spasticity, hyperreflexia, extensor plantars, pseudobulbar palsy, optic atrophy, with seizures and cognitive decline occurring only in advanced stages (e.g., MLD, Krabbe, X-ALD).
3. Basal Ganglia: Prominent extrapyramidal movement disorders (dystonia, choreoathetosis, rigidity, oculogyric crises) with preserved sensory pathways (e.g., Wilson disease, PKAN, Glutaric aciduria).
Counter-Question: What are the common causes of neuroregression based on the age of onset?• Infancy ($<1$ year): Tay-Sachs, Niemann-Pick Type A, Krabbe disease, Alpers disease, Menkes disease, Leigh syndrome.
• Early Childhood ($1-5$ years): Late-infantile NCL (CLN2), Metachromatic Leukodystrophy (MLD), Sanfilippo syndrome (MPS III), Gaucher Type 2/3.
• Late Childhood ($>5$ years): SSPE, Juvenile NCL (CLN3), X-linked Adrenoleukodystrophy (X-ALD), Wilson disease, Juvenile Huntington, Lafora disease.

2. Subacute Sclerosing Panencephalitis (SSPE): Pathogenesis & Clinical Staging

Viva Question / Counter-QuestionModel Examiner-Grade Answer
What is the virological and immunopathogenetic basis of SSPE?SSPE is a chronic, progressive, fatal neurodegenerative panencephalitis caused by a defective, persistent Measles (Rubeola) virus. The key mechanisms include:
1. Primary Infection at Early Age: Contracted natural wild-type measles typically at $<2$ years of age (immature blood-brain barrier and immature cellular immunity).
2. Viral Mutations: Accumulation of hypermutations in the measles virus genome, specifically in the Matrix (M) protein gene, and to a lesser extent the Fusion (F) and Hemagglutinin (H) genes.
3. Defective Viral Assembly: The mutated virus cannot assemble complete infectious virions or bud from cell surfaces; instead, it spreads silently from neuron to neuron and glial cells across synapses via ribonucleoprotein complexes.
4. Latency Period: Prolonged latency period of $6-10$ years before presenting with panencephalitis.
Counter-Question: Describe the Jabbour Clinical Staging for SSPE.• Stage 1 (Cognitive & Behavioral): Insidious onset; decline in school performance, forgetfulness, dysgraphia, emotional lability, lethargy, subtle personality changes.
• Stage 2 (Motor & Myoclonic): Stereotyped, periodic, synchronous Radermecker myoclonic jerks causing drop attacks; progressive spastic quadriparesis, dysarthria, apraxia, chorioretinitis, dementia.
• Stage 3 (Extrapyramidal & Rigidity): Decerebrate / decorticate posturing, severe extrapyramidal rigidity, stupor, loss of vision, intractable dysphagia.
• Stage 4 (Autonomic & Vegetative): Akinetic mutism, flexion contractures, loss of cerebral cortex function, severe autonomic instability (hyperthermia, blood pressure lability, respiratory failure), death within 1–3 years.

3. Diagnostic Hallmarks of SSPE: Dyken's Criteria & EEG

Viva Question / Counter-QuestionModel Examiner-Grade Answer
What are Dyken's Diagnostic Criteria for SSPE?Diagnosis requires 2 Major Criteria PLUS at least 1 Minor Criterion (or histological proof):

Major Criteria:
1. Clinical presentation: Progressive subacute cognitive decline and characteristic periodic myoclonus.
2. Elevated CSF Measles Antibodies: Markedly elevated anti-measles IgG antibody titers in CSF ($\ge 1:4$ ratio compared to serum) or $\ge 1:8$ in CSF alone, indicating intrathecal synthesis.

Minor Criteria:
1. Characteristic EEG: Periodic, synchronous, high-voltage slow-wave complexes (Radermecker complexes).
2. Elevated CSF IgG Index: $>0.7$ with oligoclonal bands in CSF.
3. Typical Brain Biopsy / Neuroimaging: Subcortical demyelination, gliosis, Cowdry A intranuclear inclusion bodies on biopsy.
Counter-Question: Describe the classic EEG finding in Stage 2 SSPE.Radermecker Complexes (Periodic Complexes):
• High-voltage ($300-1500\text{ }\mu\text{V}$), bilateral, symmetrical, synchronous complexes consisting of 2–3 sharp or slow waves.
• Duration of each complex: $0.5-3\text{ seconds}$.
• Periodicity: Recur rhythmically at regular intervals every $4-10\text{ seconds}$.
• Background EEG between complexes shows progressive slowing and suppression.
• Clinical Correlation: The complexes are precisely time-locked with the clinical periodic myoclonic spasms / drop attacks.
Counter-Question: What are the typical MRI Brain findings in SSPE?Early stage: Often normal or subtle asymmetric subcortical white matter T2/FLAIR hyperintensities in posterior parieto-occipital regions. Mid-to-late stage: Confluent, bilateral periventricular and deep white matter hyperintensities, corpus callosum involvement, progressive cerebral and cerebellar cortical atrophy, and ex-vacuo ventricular dilatation.

4. Evidence-Based Management & Prevention of SSPE

Viva Question / Counter-QuestionModel Examiner-Grade Answer
What are the pharmacological options for treating SSPE, and what is their clinical efficacy?There is no definitive cure; therapy aims at disease stabilization and remission induction in Stage 1 and 2:
1. Oral Inosiplex (Isoprinosine): $100\text{ mg/kg/day}$ divided 3–4 times daily (enhances T-cell mediated immunity).
2. Intraventricular Interferon-alpha ($\text{IFN-}\alpha$): $1-3\text{ million IU/m}^2$ administered weekly via a subcutaneous Ommaya reservoir for 6–12 months.
• Combination Therapy (Inosiplex + Intraventricular $\text{IFN-}\alpha$): Yields clinical stabilization or improvement in $30-40\%$ of patients compared to $<5\%$ spontaneous remission.
3. Anti-Myoclonic / Antiepileptic Control: Clonazepam ($0.05-0.1\text{ mg/kg/day}$) is first-line for periodic spasms; Sodium Valproate and Levetiracetam are effective add-on agents.
4. Palliative Care: Feeding via NG/PEG tube, chest physiotherapy, management of spasticity and contractures.
Counter-Question: How is SSPE prevented, and what is the public health impact of the MR vaccine?VIVA TRAP: SSPE is 100% preventable by Measles-Rubella (MR) vaccination. The incidence of SSPE after natural measles is approximately 1 in 10,000 cases (and as high as 1 in 600 if measles occurs at $<1$ year of age). In contrast, the risk of SSPE after measles vaccination is essentially zero or $<1$ per million. Achieving $>95\%$ two-dose coverage with MR vaccine eliminates measles and therefore eradicates SSPE.

5. Differential Diagnosis: Storage Disorders with Neuroregression & Cherry-Red Spot

Viva Question / Counter-QuestionModel Examiner-Grade Answer
Compare and contrast Tay-Sachs Disease, Niemann-Pick Disease Type A, and Gaucher Disease Type 2.1. Tay-Sachs Disease ($GM_2$ Gangliosidosis):
• Enzyme Defect: $\beta$-Hexosaminidase A (HEXA gene).
• Clinical Profile: Onset 3–6 months, severe motor regression, hyperacusis (exaggerated auditory startle), macular cherry-red spot ($>95\%$), progressive macrocephaly after 1 year.
• Key Negative: NO hepatosplenomegaly (reticuloendothelial system is spared).

2. Niemann-Pick Disease (Type A):
• Enzyme Defect: Acid Sphingomyelinase (SMPD1 gene).
• Clinical Profile: Onset 3–6 months, failure to thrive, neuroregression, cherry-red spot in $50\%$, and massive hepatosplenomegaly.

3. Gaucher Disease (Type 2 - Acute Neuronopathic):
• Enzyme Defect: Glucocerebrosidase (GBA gene).
• Clinical Profile: Onset $<6$ months, retroflexion of neck, strabismus, trismus, bulbar palsy, rapid neuroregression, massive splenomegaly, Erlenmeyer flask deformity on X-ray; cherry-red spot is rare.
Counter-Question: What causes the "Macular Cherry-Red Spot" and what is its complete differential diagnosis?• Pathophysiology: Lipids/gangliosides accumulate in the multi-layered retinal ganglion cells surrounding the fovea centralis, creating an opaque, pale, milky-white ring. The fovea itself has no ganglion cell layer, allowing the normal vascular red choroid to shine through prominently as a cherry-red spot.
• Differential Diagnosis (Mnemonic: "Cherry TREES"):
1. Tay-Sachs disease ($GM_2$ Gangliosidosis) & Sandhoff disease
2. Retinal artery occlusion (Central retinal artery occlusion - CRAO)
3. Exudative / Farber disease & Fucosidosis
4. Encephalopathy (Sialidosis / Cherry-Red Spot Myoclonus syndrome)
5. Sphingomyelinase deficiency (Niemann-Pick Type A/C) & $GM_1$ Gangliosidosis.
Counter-Question: Which neurodegenerative disorders are associated with Macrocephaly vs. Microcephaly?• Neuroregression with Macrocephaly: Alexander disease (GFAP gene, frontal white matter), Canavan disease (Aspartoacylase deficiency, elevated N-acetylaspartate), Tay-Sachs disease (after 1 year), $GM_1$ gangliosidosis, Glutaric Aciduria Type 1.
• Neuroregression with Microcephaly: Rett syndrome (MECP2 gene), Neuronal Ceroid Lipofuscinosis (NCL), Alpers disease, Angelman syndrome.

6. Leukodystrophies: MLD, Krabbe, X-ALD & Canavan Disease

Viva Question / Counter-QuestionModel Examiner-Grade Answer
What is Metachromatic Leukodystrophy (MLD) and why is it unique in showing both UMN and LMN signs?• Enzyme Defect: Deficiency of Arylsulfatase A (ARSA), leading to accumulation of sulfatide in central and peripheral myelin.
• Clinical Forms: Late-infantile (12–24 months; most common), juvenile, and adult.
• Unique Dual Feature (VIVA TRAP): Patients exhibit UMN signs (progressive spasticity, scissor gait, extensor plantars) due to central cerebral white matter demyelination, combined with LMN signs (depressed or absent deep tendon reflexes) due to concomitant demyelinating peripheral sensorimotor polyneuropathy.
• MRI Brain: Symmetrical, confluent periventricular white matter hyperintensity with sparing of subcortical U-fibers and a characteristic "tigroid" or "leopard-skin" pattern of radiating intact myelin stripes.
• Treatment: Hematopoietic Stem Cell Transplantation (HSCT) or Gene Therapy (Atidarsagene autotemcel / Libmeldy) if identified presymptomatically.
Counter-Question: What is X-linked Adrenoleukodystrophy (X-ALD)?• Genetics: X-linked recessive mutation in ABCD1 gene (Xq28), causing defective peroxisomal $\beta$-oxidation and accumulation of Very Long Chain Fatty Acids (VLCFA - C26:0, C24/C22 ratio) in white matter and adrenal cortex.
• Childhood Cerebral Form: Onset 4–8 years; behavioral deterioration, ADHD-like symptoms, scholastic drop, progressive visual/hearing loss, and spastic quadriparesis.
• Adrenal Insufficiency (Addisonian): Skin hyperpigmentation, fatigue, hypotension.
• MRI: Parieto-occipital white matter demyelination with 3 distinct zones (central necrotic, intermediate active inflammatory enhancing ring, outer non-inflammatory demyelinating).
• Therapy: Allogeneic HSCT in early stages (Loes MRI score $<9$), Lorenzo's oil (dietary), adrenal steroid replacement.

7. Neuronal Ceroid Lipofuscinoses (NCL / Batten Disease) & Cerliponase Alfa

Viva Question / Counter-QuestionModel Examiner-Grade Answer
What is Neuronal Ceroid Lipofuscinosis (NCL / Batten Disease) and what enzyme replacement therapy is currently available?NCLs are a group of autosomal recessive lysosomal storage disorders characterized by intracellular accumulation of autofluorescent ceroid-lipopigments.
• Core Clinical Tetrad: (1) Progressive neuroregression, (2) Intractable epilepsy & polymyoclonus, (3) Progressive visual failure leading to blindness (bull's eye maculopathy / optic atrophy), (4) Early dementia and motor disability.
• Late-Infantile NCL (CLN2 Disease): Caused by Tripeptidyl Peptidase 1 (TPP1) deficiency. Presents at $2-4$ years with language delay, unprovoked seizures, ataxia, and rapid motor-cognitive regression.
• Breakthrough Therapy (FDA/EMA Approved): Cerliponase alfa (Brineura) — recombinant human TPP1 administered via intracerebroventricular infusion every 2 weeks, which halts motor and language decline.
Counter-Question: What are the electron microscopic findings on skin or rectal biopsy in NCL?Biopsy of skin, conjunctiva, or rectum reveals pathognomonic ultrastructural lysosomal inclusions:
• CLN1: Granular Osmiophilic Deposits (GRODs).
• CLN2: Curvilinear bodies.
• CLN3: Fingerprint profiles.
• CLN4 / Mixed: Rectilinear profiles.
Home • © Dr. Rubanbalaji | 2026

DNB Pediatrics Practical Examination — Model Case Sheets, Proformas & Viva Questions